Shamburg News · 8-K filed Nov 18, 2026, 5:07 PM EST

Teva Announces Departure of EVP, Global R&D and Chief Medical Officer Eric Hughes

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

  • Leadership change
  • Reg FD disclosure
  • Materiality: high

On November 17, 2026, Teva Pharmaceutical Industries notified the company that Dr. Eric Hughes, Executive Vice President, Global R&D and Chief Medical Officer, intends to resign, effective immediately. In a November 18, 2026 press release furnished as Exhibit 99.1, Teva stated that David Gardiner, MD, will serve as transition lead for R&D reporting to CEO Richard Francis until a permanent successor is named. Teva said its R&D strategy and priorities remain unchanged and that it has begun a search for a successor.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 7.01, 9.01, accession 0001193125-26-467276.

Written from the filing by Shamburg Markets. Figures are as reported by the company.